
Bioceltix S.A.
Research and experimental development in natural sciences and engineering
Overview
Bioceltix is a Polish biotechnology company that develops innovative veterinary biological drugs, specifically using allogenic stem cells to treat conditions such as osteoarthritis in dogs and atopic dermatitis in both dogs and horses. The company focuses on immunomodulatory therapies targeting inflammatory and autoimmune diseases, adhering to high pharmaceutical quality standards. Bioceltix is also advancing a research project for a cell-free biological drug aimed at treating atopic dermatitis in dogs.
Financials
Revenue history (in k)
Filing timeliness
Financial statements were filed on time, on average 33 days early. All were audited by a statutory auditor.
- 202503/07/2026
- 202418/06/2025
- 202326/06/2024
- 202207/07/2023
- 202124/06/2022
- 202028/06/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Stock quotes
- Open
- PLN 68.70
- High
- PLN 69.00
- Low
- PLN 66.30
- Volume
- 3.02K
- Avg. vol.
- 4.18K
- Market cap
- PLN 371.21M
- P/E ratio
- –
- EPS
- -PLN 3.35
- Shares outstanding
- 5.53M
- 52-week
- PLN 65.00 – 72.00
- Dividend yield
- –
- Dividend
- –
- Ex dividend date
- –
- ISIN
- PLBCLTX00019
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD -17.56k | USD -1.36m | USD -1.37m |
| Q1 2026 | USD 1.89k | USD -1.56m | USD -1.53m |
| Q4 2025 | USD 0.00 | USD -857.86k | USD -850.33k |
| Q3 2025 | USD 0.00 | USD -1.12m | USD -1.10m |
Results for Q3 2026:Nov 27, 2026
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News
32/2026 Conclusion of a material agreement for the execution of a steel structure as part of the construction of a new pharmaceutical plant
31/2026 Management Board assessment of the list of questions received from the European Medicines Agency and schedule of further work in the registration process of product BCX-CM-J
30/2026 Registration of amendments to the articles of association
29/2026 Receipt of certificate of finality of the building permit decision for the investment “Biological veterinary medicines plant”
Industry
Authorized Representatives
Manner of representation
In the case of a one-person management board, the President of the Management Board is authorized to make declarations and sign on behalf of the company independently. In the case of a multi-member management board, joint action of two members of the management board, or of one member of the management board jointly with a commercial proxy, is required to make declarations and sign on behalf of the company.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2016-08-30.
19 1050 1575 1000 0090 8300 2288
03 1050 1575 1000 0090 8514 7925
27 1050 1575 1000 0025 1440 5808
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Jun 1, 2021 | Shareholders' meeting convened | |
| Dec 29, 2020 | Shareholders' meeting convened | |
| Jul 8, 2020 | Shareholders' meeting convened |
Public aid
15 public aid cases recorded, with a total value of $17,294,925.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 23, 2026 | Aid for research and development projects: industrial research | $1.4M$1,364,877 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Jun 23, 2026 | Aid for research and development projects: experimental development | $479.1K$479,112 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Jul 16, 2025 | Regional investment aid | $4.4M$4,357,905 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości |
European Funds
5 projects co-financed from European Funds recorded, with total EU co-financing of $12,633,260.
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2025-10-01 | Innovative cell-free biological medicine for veterinary applications (InnoBioVet) | $3.8M$3,796,663 | European Funds for a Modern Economy | |
| 2024-08-20 | Construction and commissioning of a pharmaceutical manufacturing plant for innovative advanced therapy veterinary medicinal products | $4.3M$4,348,078 | European Funds for a Modern Economy | |
| 2023-06-01 | Development of a biological veterinary medicinal product BCX-CM-AD for the treatment of atopic dermatitis in dogs | $2.5M$2,525,585 | European Funds for a Modern Economy |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| JJP Biologics sp. z o.o. | $4,998,735.31 | jjpbiologics.com | ||
| Captor Therapeutics S.A. | $2,286,539.43 | captortherapeutics.pl | ||
| Fileclo sp. z o.o. | $722,197.66 | fileclo.pl | ||
| Precisionlife Poland sp. z o.o. | $617,020.34 | precisionlife.com | ||
| Famicordtx S.A. | $589,673.84 | famicordtx.com | ||
| Human Biome S.A. | $583,508.16 | human-biome.com | ||
| VET Cell Tech sp. z o.o. | $483,439.81 | vetcelltech.com | ||
| Vaxican sp. z o.o. | $390,933.79 | vaxican.com | ||
| Vasa Therapeutics sp. z o.o. | $363,111.30 | vasatherapeutics.com | ||
| Multiqure S.A. | $284,781.52 | purebiologics.com |
Change history
| Date | Event | |
|---|---|---|
| 2025-11-06 | Share capital increase (492,446.80 PLN → 538,225.30 PLN) | |
| 2025-08-26 | Switch to PKD 2025 (5 PKD 2007 codes → 6 PKD 2025 codes) | |
| 2024-06-27 | Share capital increase (412,946.80 PLN → 492,446.80 PLN) | |
| 2023-07-03 | Share capital increase (397,946.80 PLN → 412,946.80 PLN) | |
| 2023-04-28 | Share capital increase (357,946.80 PLN → 397,946.80 PLN) |
FAQ
Last updated: 2026-10-07